CA2125776A1 - Pharmaceutical composition and process for the preparation thereof - Google Patents

Pharmaceutical composition and process for the preparation thereof

Info

Publication number
CA2125776A1
CA2125776A1 CA002125776A CA2125776A CA2125776A1 CA 2125776 A1 CA2125776 A1 CA 2125776A1 CA 002125776 A CA002125776 A CA 002125776A CA 2125776 A CA2125776 A CA 2125776A CA 2125776 A1 CA2125776 A1 CA 2125776A1
Authority
CA
Canada
Prior art keywords
inhibitor
phenyl
mao
composition according
uptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002125776A
Other languages
English (en)
French (fr)
Inventor
Kalman Magyar
Jozsef Gaal
Istvan Sziraki
Jozsef Lengyel
Anna Z. Szabo
Katalin Marmarosi
Istvan Hermecz
Istvan Szatmari
Zoltan Torok
Peter Kormoczy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2125776A1 publication Critical patent/CA2125776A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002125776A 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof Abandoned CA2125776A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
HU4060/91 1992-12-08

Publications (1)

Publication Number Publication Date
CA2125776A1 true CA2125776A1 (en) 1993-07-08

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125776A Abandoned CA2125776A1 (en) 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof

Country Status (27)

Country Link
US (1) US5589513A (enExample)
EP (1) EP0617615A1 (enExample)
JP (1) JPH07502730A (enExample)
KR (1) KR940703655A (enExample)
AU (1) AU677170B2 (enExample)
BG (1) BG98827A (enExample)
BR (1) BR9206950A (enExample)
CA (1) CA2125776A1 (enExample)
CZ (1) CZ147494A3 (enExample)
EC (1) ECSP930933A (enExample)
EE (1) EE03015B1 (enExample)
FI (1) FI942932A0 (enExample)
HU (2) HUT63579A (enExample)
IL (1) IL104150A (enExample)
LT (1) LT3119B (enExample)
LV (1) LV10386B (enExample)
MY (1) MY111055A (enExample)
NO (1) NO942303D0 (enExample)
NZ (1) NZ246384A (enExample)
PH (1) PH31073A (enExample)
PL (1) PL172048B1 (enExample)
RO (1) RO115785B1 (enExample)
RU (1) RU2125448C1 (enExample)
SI (1) SI9200404A (enExample)
SK (1) SK74494A3 (enExample)
WO (1) WO1993012775A1 (enExample)
ZA (1) ZA929883B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (de) * 1994-09-13 1996-02-01 Knoll Ag Verfahren zur Herstellung von Selegilin-Hydrochlorid
AU723047B2 (en) * 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (hu) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. P-fluoro-selegilin alkalmazása neuroprotektív gyógyszerkészítmények előállítására
RU2194983C2 (ru) * 2000-06-30 2002-12-20 Научно-исследовательский институт военной медицины Способ оценки нейротоксичности сыворотки крови больных с заболеваниями печени
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (de) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Fleckenvorbehandlungsmittel
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. TESTOSTERONE UNDECANOATE ORAL TREATMENT
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Also Published As

Publication number Publication date
WO1993012775A1 (en) 1993-07-08
PL172048B1 (pl) 1997-07-31
PH31073A (en) 1998-02-05
HU914060D0 (en) 1992-03-30
KR940703655A (ko) 1994-12-12
BG98827A (bg) 1995-06-30
HUT63579A (en) 1993-09-28
FI942932L (fi) 1994-06-17
RO115785B1 (ro) 2000-06-30
AU3265293A (en) 1993-07-28
HU211478A9 (en) 1995-11-28
ZA929883B (en) 1994-05-16
NZ246384A (en) 1996-02-27
US5589513A (en) 1996-12-31
JPH07502730A (ja) 1995-03-23
FI942932A7 (fi) 1994-06-17
EP0617615A1 (en) 1994-10-05
NO942303D0 (no) 1994-06-17
AU677170B2 (en) 1997-04-17
LV10386B (en) 1995-12-20
IL104150A (en) 1997-11-20
SK74494A3 (en) 1995-01-12
NO942303L (enExample) 1994-08-17
LT3119B (en) 1994-12-27
RU2125448C1 (ru) 1999-01-27
ECSP930933A (es) 1994-04-20
FI942932A0 (fi) 1994-06-17
CZ147494A3 (en) 1995-01-18
SI9200404A (en) 1993-06-30
BR9206950A (pt) 1995-11-28
EE03015B1 (et) 1997-08-15
LTIP249A (en) 1994-07-15
LV10386A (lv) 1995-02-20
MY111055A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
CA2125776A1 (en) Pharmaceutical composition and process for the preparation thereof
BE1001467A3 (fr) Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament.
DK175085B1 (da) Farmaceutisk præparat med forlænget frigivelse af et dihydropyridin og en beta-adrenoreceptorantagonist samt fremgangsmåde til fremstilling heraf
FI91826C (fi) Menetelmä kiinteän valmisteen valmistamiseksi, josta aktiivista yhdistettä vapautuu pidennetyn ajanjakson ajan
RU2157685C2 (ru) Фармацевтическая композиция с антидепрессивной активностью
NO303903B1 (no) Vannfritt transdermalt preparat
FR2774591A1 (fr) Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
CA2245836A1 (en) Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
JPH06501680A (ja) 生体内の自己以外の細胞を排除するオートバイオチクスおよびそれらの使用
US5854287A (en) D-Propranolol metabolites useful for antioxidant activities
US20160346249A1 (en) Use of amitifadine, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in methods and compositions with enhanced efficacy and reduced metabolic side effects and toxicity for treatment of depression and other central nervous system disorders and conditions affected by monoamine neurotransmitters
MXPA00012248A (es) Incrementadores de acetilcolina.
US3360434A (en) Method for reducing blood pressure with phenylalanine derivatives
Tabei et al. Antihypertensive and noradrenaline-depleting effects of α-methyl-5-hydroxytryptophan in the rat
CA1197191A (fr) Composition pharmaceutique antihypertensive synergetique
BE1000087A3 (fr) Compositions pharmaceutiques contenant de la vinburnine et leur procede de preparation.
IE60533B1 (en) An oral osmotic system for metoprolol with improved formulation properties
DE69713271T2 (de) Verstärker der blutplättchenfunktionund verfahren zur behandlung der blut plättchenfunktionsstörung
Koe et al. Inhibition of rat brain tryptophan hydroxylation with p-chloroamphetamine
CA2022447A1 (fr) Forme galenique orale ameliorant la biodisponibilite
RU2277910C2 (ru) Средство "форинит-гель" для лечения и профилактики сердечно-сосудистых заболеваний
Albert Comparative distribution: the first principle of selectivity
NL195081C (nl) Fenylcarbamaat.
PT91736B (pt) Processo para a rpeparacao de produtos farmac}euticos contendo derivados acilo de dianidro_hexitois
Moore Nitric oxide as a bioregulator

Legal Events

Date Code Title Description
FZDE Discontinued